OXFORD, Ohio and COCONUT CREEK, Fla., Dec. 1, 2021 /CNW/ - PsyBio Therapeutics
Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the
"Company"), an intellectual property driven biotechnology
company focusing on discovering and developing new, bespoke,
psycho-targeted therapeutics to potentially improve mental and
neurological health, today announced that Evan Levine, Chief Executive Officer and
Chairman, will present at the H.C. Wainwright 2nd Annual
Psychedelics Conference.
Date:
|
Monday, December 6,
2021
|
Time:
|
On-demand beginning
at 7:00 a.m. Eastern Time
|
Link:
|
https://journey.ct.events/view/013634f9-6376-4da3-b946-3ecb38454d3f
|
A recording of the presentation will be accessible on PsyBio's
website via the above link for 90 days.
The PsyBio management team will be available for one-on-one
meetings throughout the conference. To schedule a meeting, please
contact your H.C. Wainwright representative or KCSA Strategic
Communications by emailing PsyBio@kcsa.com.
About PsyBio Therapeutics Corp.
PsyBio is an intellectual property driven biotechnology company
focusing on discovering and developing new, bespoke,
psycho-targeted therapeutics to potentially improve mental and
neurological health. The team has extensive experience in drug
discovery based on synthetic biology and metabolic engineering as
well as clinical and regulatory expertise progressing drugs through
human studies and regulatory protocols. Research and development is
currently ongoing for naturally occurring psychoactive tryptamines
originally discovered in different varieties of hallucinogenic
mushrooms, other tryptamines and phenethylamines and combinations
thereof. The Company utilizes a bio-medicinal chemistry approach to
therapeutic development, in which psychoactive compounds can be
utilized as a template upon which to develop precursors and
analogs, both naturally and non-naturally occurring.
PsyBio makes no medical, treatment or health benefit claims
about PsyBio's proposed products. The U.S. Food and Drug
Administration ("FDA") or other similar regulatory
authorities have not evaluated claims regarding psilocybin and
other next generation psychoactive compounds. The efficacy of such
products has not been confirmed by FDA- approved research. There is
no assurance that the use of psilocybin and other psychoactive
compounds can diagnose, treat, cure, or prevent any disease or
condition. Vigorous scientific research and clinical trials are
needed. PsyBio has not conducted clinical trials for the use of its
intellectual property. Any references to quality, consistency,
efficacy and safety of potential products do not imply that PsyBio
verified such in clinical trials or that PsyBio will complete such
trials. If PsyBio cannot obtain the approvals or research necessary
to commercialize its business, it may have a material adverse
effect on the PsyBio's performance and operations.
The TSX Venture Exchange ("TSXV") has neither approved
nor disapproved the contents of this news release. Neither the TSXV
nor its Regulation Services Provider (as that term is defined in
the policies of the TSXV) accepts responsibility for the adequacy
or accuracy of this release.
SOURCE PsyBio Therapeutics Corp.